Authors
Song Hu, Yuqi Xie, Jiang-Shan Tan, Ting-Ting Guo, Shengsong Zhu, Zhennan Lin, Jian Zhang, Lu Hua
Published in
iScience. Volume 29. Issue 11. Pages 117792. Nov 20, 2026. Epub Oct 07, 2026.
Abstract
Pulmonary arterial hypertension (PAH) remains a progressive disease with high mortality. By integrating the UK Biobank Pharma Proteomics Project (49,272 participants, 337 incident cases) with drug-target Mendelian randomization, we identified 398 plasma proteins associated with incident PAH and 19 with potential causal relevance, 15 of which are druggable. Then we prioritized 5 candidates for expression validation in the Sugen5416 and hypoxia rat model and confirmed significant upregulation of TNFRSF10A and downregulation of UMOD in lung tissue, consistent with human plasma proteomic trends. Subsequent in vitro functional assays demonstrated that UMOD treatment attenuates PAH-related cellular phenotypes, whereas TNFRSF10A knockdown exacerbates pro-pathogenic progression. These results suggest UMOD as a promising protective therapeutic candidate and indicate the inherent complexity of the TNFRSF10A signaling. This integrative study provides a robust framework for translational research, future studies are warranted to elucidate downstream molecular mechanisms and further evaluate the therapeutic efficacy of these candidates.
PMID:
42894645
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0